Achilles Therapeutics (NASDAQ:ACHL – Get Rating) had its price target dropped by research analysts at Chardan Capital from $17.00 to $12.00 in a research report issued on Wednesday, The Fly reports.
A number of other equities analysts also recently weighed in on ACHL. Oppenheimer downgraded Achilles Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday, December 6th. Piper Sandler decreased their target price on Achilles Therapeutics from $10.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, December 6th.
Get Achilles Therapeutics alerts:Achilles Therapeutics Trading Down 4.3 %
Shares of ACHL stock opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market capitalization of $38.96 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. Achilles Therapeutics has a 52-week low of $0.75 and a 52-week high of $3.45. The company has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $1.75.
Hedge Funds Weigh In On Achilles Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of Achilles Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 10,450 shares of the company's stock valued at $31,000 after buying an additional 5,922 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Achilles Therapeutics during the third quarter worth about $39,000. Sei Investments Co. purchased a new position in shares of Achilles Therapeutics in the second quarter worth about $59,000. Renaissance Technologies LLC raised its position in shares of Achilles Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 30,533 shares of the company's stock valued at $90,000 after purchasing an additional 5,000 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Achilles Therapeutics during the 4th quarter valued at approximately $28,000. 69.66% of the stock is owned by institutional investors.
Achilles Therapeutics Company Profile
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Read More
- Get a free copy of the StockNews.com research report on Achilles Therapeutics (ACHL)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.